Difference between revisions of "Staging page"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m (Blanked the page)
Tag: Blanking
 
(45 intermediate revisions by 2 users not shown)
Line 1: Line 1:
−
<span id="BackToTop"></span>
+
 
−
<div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px">
 
−
[[#top|Back to Top]]
 
−
</div>
 
−
{{#lst:Section editor transclusions|tcl}}
 
−
{| class="wikitable" style="float:right; margin-right: 5px;"
 
−
|-
 
−
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
 
−
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
 
−
|}
 
−
{{TOC limit|limit=3}}
 
−
=Guidelines=
 
−
=="How I Treat"==
 
−
*'''2012:''' Dearden [https://ashpublications.org/blood/article/120/3/538/30480/How-I-treat-prolymphocytic-leukemia How I treat prolymphocytic leukemia]
 
−
 
−
==[https://www.nccn.org/ NCCN]==
 
−
*[https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf NCCN Guidelines - T-cell Lymphomas]
 
−
=Diagnosis, staging and treatment response criteria (TPLL-ISG)=
 
−
*'''2019:''' Staber et al. [https://doi.org/10.1182/blood.2019000402 Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia]
 
−
=Upfront induction therapy=
 
−
==Alemtuzumab monotherapy {{#subobject:ab5318|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:893a|Variant=1}}===
 
−
{| class="wikitable" style="width: 60%; text-align:center;"
 
−
!style="width: 33%"|Study
 
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
 
−
|-
 
−
|[https://doi.org/10.1182/blood.v98.6.1721 Dearden et al. 2001]
 
−
| style="background-color:#91cf61" |Non-randomized
 
−
|ORR: 76%, CR: 60%
 
−
|-
 
−
|[https://doi.org/10.1182/blood-2011-08-372854 Dearden et al. 2011]
 
−
| style="background-color:#91cf61" |Non-randomized
 
−
|ORR: 91%, CR: 81%
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Targeted therapy====
 
−
* [[Alemtuzumab (Campath)]] as follows:
 
−
**Week 1: 3 mg IV once on day 1, then 10 mg IV once on day 2, then 30 mg IV once on day 3
 
−
**Week 2 onwards: 30 mg IV three times weekly
 
−
'''Continued until achievement of CR or best response or for up to a total of 3 months'''
 
−
</div></div>
 
−
===References===
 
−
#Dearden CE, Matutes E, Cazin B, Tjønnfjord GE, Parreira A, Nomdedeu B, Leoni P, Clark FJ, Radia D, Rassam SM, Roques T, Ketterer N, Brito-Babapulle V, Dyer MJ, Catovsky D. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001 Sep 15;98(6):1721-6. [https://doi.org/10.1182/blood.v98.6.1721 link to original article] [https://pubmed.ncbi.nlm.nih.gov/11535503 PubMed]
 
−
#Dearden CE, Khot A, Else M, Hamblin M, Grand E, Roy A, Hewamana S, Matutes E, Catovsky D. Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. Blood. 2011 Nov 24;118(22):5799-802. Epub 2011 Sep 26. [https://doi.org/10.1182/blood-2011-08-372854 link to original article] [https://pubmed.ncbi.nlm.nih.gov/21948296 PubMed]
 
−
==Pentostatin & Alemtuzumab {{#subobject:aacb018|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:881cj3a|Variant=1}}===
 
−
{| class="wikitable" style="width: 60%; text-align:center;"
 
−
!style="width: 33%"|Study
 
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
 
−
|-
 
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881363/ Ravandi et al. 2009 (MDACC 2004-0408)]
 
−
| style="background-color:#91cf61" |Non-randomized
 
−
|ORR: 69%, CR: 62%
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Targeted therapy====
 
−
*[[Alemtuzumab (Campath)]] as follows:
 
−
**Week 1: 3 mg IV once on day 1, then 10 mg IV once on day 2, then 30 mg IV once on day 3
 
−
**Week 2 onwards: 30 mg IV three times weekly
 
−
====Chemotherapy====
 
−
*[[Pentostatin (Nipent)]] as follows:
 
−
**Weeks 1 to 4: 4 mg/m<sup>2</sup> IV once per week
 
−
**Week 5 onwards: 4 mg/m<sup>2</sup> IV once every 2 weeks
 
−
'''Continued until achievement of CR or best response or for up to a total of 3 months (total of 14 doses of pentostatin)'''
 
−
</div></div>
 
−
===References===
 
−
#'''MDACC 2004-0408:''' Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol. 2009 Nov 10;27(32):5425-30. Epub 2009 Oct 5. [https://doi.org/10.1200/JCO.2009.22.6688 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881363/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/19805674 PubMed]
 
−
=Relapsed or refractory, salvage therapy=
 
−
==Bendamustine monotherapy {{#subobject:a1kc88|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:90ucj3a|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
! style="width: 25%" |Study
 
−
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/full/10.1111/bjh.13175 Herbaux et al. 2014]
 
−
| style="background-color:#ffffbe" |Retrospective
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
* [[Bendamustine]] 70 to 120 mg/m<sup>2</sup> IV once per day on days 1 & 2
 
−
'''21-day cycle for 6 cycles'''
 
−
</div></div>
 
−
===References===
 
−
# '''Retrospective:''' Herbaux C, Genet P, Bouabdallah K, Pignon JM, Debarri H, Guidez S, Betrian S,  Leleu X, Facon T, Morschhauser F, Damaj G, Cazin B, Ysebaert L. Bendamustine is effective in T-cell prolymphocytic leukaemia. Br J Haematol. 2015 Mar;168(6):916-9. [https://doi.org/full/10.1111/bjh.13175 link to original article] [https://pubmed.ncbi.nlm.nih.gov/25316212 PubMed]
 
−
==Pentostatin & Alemtuzumab {{#subobject:a1kb018|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:991cj3a|Variant=1}}===
 
−
{| class="wikitable" style="width: 60%; text-align:center;"
 
−
!style="width: 33%"|Study
 
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
 
−
|-
 
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881363/ Ravandi et al. 2009 (MDACC 2004-0408)]
 
−
| style="background-color:#91cf61" |Non-randomized
 
−
|ORR: 69%, CR: 62%
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Targeted therapy====
 
−
*[[Alemtuzumab (Campath)]] as follows:
 
−
**Week 1: 3 mg IV once on day 1, then 10 mg IV once on day 2, then 30 mg IV once on day 3
 
−
**Week 2 onwards: 30 mg IV three times weekly
 
−
====Chemotherapy====
 
−
*[[Pentostatin (Nipent)]] as follows:
 
−
**Weeks 1 to 4: 4 mg/m<sup>2</sup> IV once per week
 
−
**Week 5 onwards: 4 mg/m<sup>2</sup> IV once every 2 weeks
 
−
'''Continued until achievement of CR or best response or for up to a total of 3 months (total of 14 doses of pentostatin)'''
 
−
</div></div>
 
−
===References===
 
−
#'''MDACC 2004-0408:''' Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol. 2009 Nov 10;27(32):5425-30. Epub 2009 Oct 5. [https://doi.org/10.1200/JCO.2009.22.6688 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881363/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/19805674 PubMed]
 
−
==Ibrutinib & Venetoclax {{#subobject:a1uh18|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:991ica|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 50%"|Study
 
−
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://ashpublications.org/blood/article/134/Supplement_1/3965/424160/Combination-of-Venetoclax-and-Ibrutinib-Increases Kornauth et al. 2019]
 
−
| style="background-color:#91cf61" |Non-randomized
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Targeted therapy====
 
−
* [[Ibrutinib (Imbruvica)|Ibrutinib]] 420 mg PO once per day
 
−
* [[Venetoclax (Venclexta)|Venetoclax]] 400 to 600 mg PO once per day
 
−
'''Continued indefinitely'''
 
−
</div></div>
 
−
===References===
 
−
# '''Abstract:''' Kornauth C, Herbaux C, Boidol B, Guillemette C, Caron P, Poulain S, et al. Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia. Blood. 2019;134(Supplement_1):3965. [https://ashpublications.org/blood/article/134/Supplement_1/3965/424160/Combination-of-Venetoclax-and-Ibrutinib-Increases link to abstract]
 
−
=Consolidation therapy after upfront or salvage therapy=
 
−
'''[[Allogeneic HSCT]]''' evaluation suggested in eligible patients.
 
−
</div></div>
 
−
===References===
 
−
# Krishnan B, Else M, Tjonnfjord GE, Cazin B, Carney D, Carter J, Ketterer N, Catovsky D, Ethell M, Matutes E, Dearden CE. Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study. Br J Haematol. 2010 Jun;149(6):907-10. [https://doi.org/full/10.1111/j.1365-2141.2010.08134.x link to original article] [https://pubmed.ncbi.nlm.nih.gov/20201944 PubMed]
 
−
# Kalaycio ME, Kukreja M, Woolfrey AE, Szer J, Cortes J, Maziarz RT, Bolwell BJ, Buser A, Copelan E, Gale RP, Gupta V, Maharaj D, Marks DI, Pavletic SZ, Horowitz  MM, Arora M. Allogeneic hematopoietic cell transplant for prolymphocytic leukemia. Biol Blood Marrow Transplant. 2010 Apr;16(4):543-7. [https://doi.org/10.1016/j.bbmt.2009.11.021 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2839005/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/19961946 PubMed]
 
−
# '''Retrospective:''' Wiktor-Jedrzejczak W, Dearden C, de Wreede L, van Biezen A, Brinch L, Leblond  V, Brune M, Volin L, Kazmi M, Nagler A, Schetelig J, de Witte T, Dreger P; EBMT Chronic Leukemia Working Party. Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium. Leukemia. 2012 May;26(5):972-6. [https://www.nature.com/articles/leu2011304 link to original article] [https://pubmed.ncbi.nlm.nih.gov/22116553 PubMed]
 
−
[[Category:T-cell prolymphocytic leukemia regimens]]
 
−
[[Category:Disease-specific pages]]
 
−
[[Category:T-cell leukemias]]
 

Latest revision as of 00:13, 18 June 2023

Retrieved from "https://hemonc.org/w/index.php?title=Staging_page&oldid=73776"